PRODIGE 24 / CCTG PA6
Showed that giving the strong four-drug chemotherapy after pancreatic surgery adds years of life for fit patients.
493 patients. Median OS 54.4 vs 35.0 months (HR 0.64) and DFS 21.6 vs 12.8 months. Established mFOLFIRINOX as adjuvant standard in fit patients (NEJM 2018; 5-year update 2022).
- Median 21.6 vs 12.8 months with Adjuvant mFOLFIRINOX compared with Adjuvant gemcitabine; about 8.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 42 percent lower chance of the event at any given time (hazard ratio 0.58, likely range 0.46 to 0.73).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 53.5 vs 35.5 months with Adjuvant mFOLFIRINOX compared with Adjuvant gemcitabine; about 18 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 32 percent lower chance of the event at any given time (hazard ratio 0.68).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Adjuvant therapy after resection of PDAC: mFOLFIRINOX vs gemcitabine. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
493 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survivalprimary | Adjuvant mFOLFIRINOX | 247 | 21.6 months | 0.58 (0.46–0.73) | <0.001 | link |
| Adjuvant gemcitabine | 246 | 12.8 months | ||||
| Overall survival (5-year update) | Adjuvant mFOLFIRINOX | — | 53.5 months | 0.68 | — | link |
| Adjuvant gemcitabine | — | 35.5 months |
Pages like this
not linked directly; found by shared links- TrialPREOPANC-1 / PREOPANC-2
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- TrialNAPOLI 3
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.
- ProductFOLFOX (5-FU, leucovorin, oxaliplatin)
Shares FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma.